Ignite Creation Date:
2025-12-24 @ 6:47 PM
Ignite Modification Date:
2025-12-28 @ 1:43 AM
Study NCT ID:
NCT05286957
Status:
RECRUITING
Last Update Posted:
2023-03-17
First Post:
2022-03-01
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
MRD-guided Adjuvant Tislelizumab and Chemotherapy in Resected Stage IIA-IIIB NSCLC
Sponsor:
The First Affiliated Hospital of Zhengzhou University
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-06-20
Start Date Type:
ACTUAL
Primary Completion Date:
2026-06-01
Primary Completion Date Type:
ESTIMATED
Completion Date:
2027-06-01
Completion Date Type:
ESTIMATED
First Submit Date:
2022-03-01
First Submit QC Date:
None
Study First Post Date:
2022-03-18
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-03-15
Last Update Post Date:
2023-03-17
Last Update Post Date Type:
ACTUAL